
Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint ® and BluePrint ®
Agendia, Inc., a world leader in precision oncology for breast cancer, announced new 5-year data from the NBRST trial that will be presented in a poster spotlight discussion Thursday, December 10, 2020 from 3:30pm-4:45pm CST at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020).
The poster, entitled 5-year outcomes in the NBRST trial: Preoperative MammaPrint® and BluePrint® breast cancer subtype is associated with neoadjuvant treatment response and survival, contains the largest data set evaluating a genomic test in the neoadjuvant setting with long-term outcomes. These outcomes demonstrate the predictive and prognostic abilities of MammaPrint® and BluePrint®, and underpin both assays’ pre-operative utility.
In the 5-year results of the Neoadjuvant Breast Symphony Trial (NBRST), 22% of the tumors evaluated were reclassified from their original clinical subtype into a different molecular subtype by MammaPrint and BluePrint. This reclassification has significant implications for treatment planning, reinforcing the importance of the multi-disciplinary care team having this meaningful information at the earliest point after diagnosis to inform the decision for the timing of surgery and systemic therapy.
Importantly, the reclassification by BluePrint allowed researchers to detect more genomic diversity within pathologically ER+ and HER2 negative breast cancers than previously thought. 18% of those tumors were reclassified as Basal-Type by BluePrint (ER+/Basal) while 44% of pathologically HER2+ tumors were reclassified as Luminal- or Basal-Type by BluePrint. Of note, the response to treatment and longer term outcomes in those reclassified patients were distinctly different and aligned with the subtype identified by BluePrint.
“Genomic classification is uncovering the diversity in these pathologically-defined subsets,” said Pat Whitworth, M.D., first author of the spotlight poster and a breast surgical oncologist at the Nashville Breast Center. “If a conventional HER2+ or an ER+/HER2 negative tumor is reclassified as BluePrint Basal-Type, switching to a different treatment approach, such as a HER2-targeted regimen with optimal basal coverage or different timing for surgery, may improve outcomes for those patients. With this extra layer of information, the patient and her care team are able to make important decisions at the very beginning of their journey that will be felt years down the line. Just as important, these patients should be the focus of upcoming trials.”
In looking into the genomic makeup of the tumors, BluePrint could further stratify ER+ and HER2+ breast cancers as Luminal- or Basal-Type, which respond differently to treatment and could one day impact how these patients are treated. This observation echoes what was seen in a subanalysis of the APHINITY trial, also part of a spotlight poster discussion at SABCS 2020.
“The finding that a subset of ER+ HER2 negative primary breast cancers has a basal genotype on BluePrint analysis is a novel and very provocative result that compels us to study this further,” said Joyce O’Shaughnessy, M.D., Director of the Breast Cancer Research Program for Texas Oncology and the US Oncology Network. “Should the ER+/basal breast cancers be treated as triple negative breast cancers, with platinum-based regimens, capecitabine post-op for residual disease and potentially with preop checkpoint inhibitors? We plan to study preop administration of platinum-based chemotherapy in patients with ER+/basal cancer to determine whether their outcomes parallel those of triple negative basal breast cancers.”
Also presented at SABCS 2020 is a supporting poster on the NBRST study, “Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification,” which focused on the discordant groups within the 22% of BluePrint reclassifications displayed in the NBRST study. The data showed that molecular subtyping using MammaPrint and BluePrint is additive to pathologic assessment and thus facilitates more informed treatment decisions.
In addition, the supplemental NBRST poster reinforces the importance of genomic testing to further stratify Luminal patients. The data showed that Luminal A-Type patients have excellent outcomes on neoadjuvant endocrine therapy alone, an important consideration during the COVID-19 pandemic, while Luminal B-Type patients need additional systemic treatment.
According to James Pellicane, M.D., Director of Breast Oncology at the Bon Secours Cancer Institute, “These data confirm that BluePrint can be utilized as a tool to determine whether neoadjuvant systemic therapy or surgery followed by adjuvant therapy is the best option for a patient based on the molecular subtype of their breast cancer and its predicted response to therapy. What we’ve seen from NBRST is that certain patients, specifically the Luminal A subtypes, will respond to neoadjuvant endocrine therapy and have good long-term outcomes postoperatively with endocrine therapy alone. Others may respond to neoadjuvant endocrine therapy but because of their more aggressive biology, specifically the Luminal B subtypes, will benefit from cytotoxic chemotherapy in the adjuvant or sometimes in the neoadjuvant setting. As a surgeon, it’s comforting to know that you can triage these patients more effectively, having a better understanding of the biology of their breast cancer and how it will respond to different treatment algorithms and how that response corresponds with their long-term outcome.”
These data are part of a large suite of 13 posters, spotlight sessions and an oral presentation on MammaPrint and BluePrint that were accepted to SABCS 2020, and underscore Agendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005146/en/
Contact information
Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo